Letter to the Editor: the nonnegligible effect of neoadjuvant therapy for patients with borderline resectable pancreatic ductal adenocarcinoma

Li Wang¹, Xin Zhang¹, Yanrong Lu¹, Bole Tian¹

¹Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, China

Correspondence to: Professor Bole Tian. Department of Pancreatic Surgery, West China Hospital, Sichuan University, 37# Guoxue Alley, Chengdu, China. Email: tianbole@163.com.


Submitted Jun 08, 2021. Accepted for publication Jun 30, 2021.
doi: 10.21037/gs-21-379

View this article at: https://dx.doi.org/10.21037/gs-21-379

To date, R0 resection still remains the standard curative approach for pancreatic ductal adenocarcinoma (PDAC). Due to multiple factors including technical refinements, mortality in pancreatic surgery has dropped below 3%. In contrast, postoperative morbidity following pancreatectomy occurs in more than one third of all patients undergoing pancreatectomies (1). Numerous articles on improving the outcomes of these patients have been published these years. Recently, we read with great interest the article by Wang and colleagues regarding the related factors affecting the prognosis of pancreatic carcinoma with portal venous system invasion (2). We congratulate the authors for this interesting study. They evaluated the prognosis of 118 pancreatic cancer patients with portal venous system invasion who underwent curative resection, and found that the venous invasion depth was an independent risk factor for the prognosis of these patients. Meanwhile, 47 of the included patients have adjuvant chemotherapy during follow-up period. However, unexpectedly, they didn’t provide any data about preoperative NAT which was advised for borderline resectable PDAC patients by the guidelines. As the author mentioned in the discussion section, it still remains controversial on the indication of neoadjuvant therapy. The overall effective rate of chemotherapy for pancreatic cancer is less than 30%, while the effect of this regimen is even worse for Chinese patients (2). As a result, the extensive adoption of NAT may cause delays in the timing of surgery. Even so, if they could show the proportion of NAT in their cohort and the corresponding prognostic effects, the readers may understand and cite the results more precisely.

On the other hand, we notice they have mentioned the postoperative morbidity of the 118 patients, including biochemical fistula (n=10) and clinical postoperative pancreatic fistula (n=5). Recently, we have performed a brief meta-analysis, which has not been published elsewhere, just to elucidate the effect of NAT on preventing postoperative pancreatic fistula in patients with PDAC. Indeed, several recent studies have reported postoperative clinical pancreatic fistula with or without NAT preoperatively (3-9). And the pooled results of these studies demonstrated that the administration of NAT had a beneficial effect on reducing the risk of clinical pancreatic
fistula (grade B and C) for patients with surgical treated pancreatic cancer (OR, 0.42; 95% confidence interval, 0.33 to 0.54; P<0.001) (Figure 1). However, none of these studies including Chinese patients. Thus, we are curious about the corresponding results of this study which reflect the outcomes of Chinese PDAC patients.

Indeed, by reducing tumor bulk and involvement of nearby structures, NAT is increasingly being utilized in borderline resectable and locally advanced pancreatic cancer to increase resectability and improve margin negative resection rates, but with a risk of delays in the timing of surgery and tumor progression. Thus, it still remains controversial among scholars, especially for surgeons. Interestingly, there is mounting evidence indicating that NAT is able to reduce the risk of pancreatic fistula besides its fundamental role in downstaging pancreatic tumors and improving survival outcomes, which was confirmed by the pooled results indicated above. Theoretically, this may be explained by the pancreatic fibrosis and lobular atrophy, and the subsequent harder gland texture and poorer exocrine function of the pancreas following NAT (10).

In conclusion, we congratulate the authors for the remarkable study, which add significant value and information to the debate on the surgical strategy and relative prognosis of patients with borderline resectable PDAC. Meanwhile, further discussion and studies are needed to assess the effects of NAT for Chinese PDAC patients.

**Acknowledgments**

**Funding:** This study was supported by the post-doctor research project, West China Hospital, Sichuan University (2020HXBH046).

**Footnote**

**Provenance and Peer Review:** This article was a standard submission to the journal. The article did not undergo external peer review.

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/gs-21-379). The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and

---

**Figure 1** Forest plots of the effects of NAT on clinical pancreatic fistula for PDAC patients. NAT, neoadjuvant therapy; PDAC, pancreatic ductal adenocarcinoma; OR, odds ratio; CI, confidence interval.
the original work is properly cited (including links to both
the formal publication through the relevant DOI and the
license). See: https://creativecommons.org/licenses/by-nc-
nd/4.0/.

References

1. Beger HG, Mayer B. Early postoperative and late
metabolic morbidity after pancreatic resections: An old
pancreatic carcinoma with portal system invasion following
chemoradiation for initially unresectable or borderline
resectable pancreatic adenocarcinoma increase post-
operative morbidity? A case-matched analysis. HPB
of Neoadjuvant Systemic Therapy on Pancreatic Fistula
Rates Following Pancreatectomy: a Population-Based
Propensity-Matched Analysis. J Gastrointest Surg
Between Pancreatic Fistula and Long-term Survival in
the Era of Neoadjuvant Chemotherapy. JAMA Surg
Therapy in Resected Pancreatic Ductal Adenocarcinoma
of the Pancreatic Body or Tail on Surgical and Oncological
Outcome: A Propensity-Score Matched Multicenter Study.
Therapy Versus Upfront Resection for Pancreatic Cancer:
The Actual Spectrum and Clinical Burden of Postoperative
chemoradiation therapy using S-1 followed by surgical
resection in patients with pancreatic cancer. J Gastrointest
chemoradiation reduces the risk of pancreatic fistula after
distal pancreatectomy for pancreatic adenocarcinoma.
Surgery 2011;150:547-56.
intraepithelial neoplasia and histological changes in non-
neoplastic pancreas associated with neoadjuvant therapy
in patients with pancreatic ductal adenocarcinoma.

Cite this article as: Wang L, Zhang X, Lu Y, Tian B. Letter
to the editor: the nonnegligible effect of neoadjuvant therapy
for patients with borderline resectable pancreatic ductal
gs-21-379